Loading...
skip to Main Content
Register with early fees
Add to Calendar 2021-10-07 2021-10-09 America/Los_Angeles Bleeding, Thrombosis, and Vascular Liver Diseases Crowne Plaza Geneva | Geneva, Switzerland

EASL is delighted to announce the launch of Bleeding, Thrombosis, and Vascular Liver Diseases, taking place 7–9 October in Geneva (Switzerland).

Liver disease is associated with haemostatic alterations that may lead to both bleeding and thrombotic complications that are an important cause of morbidity and mortality. This EASL–VALDIG meeting will focus on the pathogenesis and management of patients with haemostatic alterations. Special interest will be paid to multidisciplinary management and identification of future areas of research.

The programme will outline the current and newly generated evidence regarding haemostatic alterations, in relation to thrombosis and bleeding complications in patients with liver disease. The programme will cover the main areas of interest such us management of haemostatic alterations in patients undergoing invasive procedures and treatment of portal vein thrombosis (PVT) in liver transplant candidates. A part of the programme will be dedicated to reviewing the new data generated in the field of vascular liver diseases. To highlight the importance of the multidisciplinary management and the strong need to perform collaborative studies, we will provide a mix of speakers, from different clinical and scientific backgrounds, patient organisations, and European policy officers.  Moreover, we will revise and compare the available guidelines on haemostasis in patients with liver disease.

Learning objectives

Participants will be able to expand their knowledge about current and emerging insights in pathogenesis, diagnostic challenges, and novel therapeutic strategies of bleeding and thrombosis in patients with liver diseases.

Specific learning objectives:

  • Update on the mechanisms leading to PVT and its optimal clinical treatment
  • Management of haemostasis in patients undergoing invasive procedures
  • Discussion of new evidence generated in the field of vascular liver diseases
  • Awareness of the controversies regarding management of thrombocytopenia
  • Detailed knowledge of the current scientific guidelines on haemostasis in liver diseases

Scope

  • Coagulation alterations
  • Thrombocytopenia and patients under anti-platelet/anticoagulant drugs
  • Vascular liver disorders
  • Portal vein thrombosis

Who should attend

Personnel involved in the management of liver patients:

  • hepatologists,
  • gastroenterologists,
  • radiologists,
  • interventional radiologists,
  • haematologists,
  • surgeons,
  • anaesthesiologists,
  • intensive care doctors and nurses,
  • scientists interested in haemostasis and/or liver disease.
Back To Top